Freitag, 16. April 2021
Navigation öffnen
Anzeige:
Lonsurf
 
JOURNAL ONKOLOGIE – STUDIE

BI 894999 First in Human Dose Finding Study in Advanced Malignancies

Rekrutierend

NCT-Nummer:
NCT02516553

Studienbeginn:
Juli 2015

Letztes Update:
08.04.2021

Wirkstoff:
BI 894999

Indikation (Clinical Trials):
Carcinoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 1

Sponsor:
Boehringer Ingelheim

Collaborator:
-

Studienleiter

Boehringer Ingelheim
Study Chair
Boehringer Ingelheim

Kontakt

Boehringer Ingelheim Call Center
Kontakt:
Phone: 1-800-243-0127
E-Mail: clintriage.rdg@boehringer-ingelheim.com
» Kontaktdaten anzeigen

Studienlocations
(3 von 19)

Viszeralonkologisches Zentrum Universitätsklinikum Tübingen
Hoppe-Seyler-Straße 3
72076 Tübingen
DeutschlandRekrutierend» Google-Maps
University of Southern California
90033 Los Angeles
United StatesRekrutierend» Google-Maps
Dana-Farber Cancer Institute
02215 Boston
United StatesRekrutierend» Google-Maps
Memorial Sloan-Kettering Cancer Center
10021 New York
United StatesRekrutierend» Google-Maps
The University of Texas MD Anderson Cancer Center
77030 Houston
United StatesRekrutierend» Google-Maps
Brussels - HOSP Jules Bordet
1000 Brussels
BelgiumRekrutierend» Google-Maps
Seoul National University Hospital
03080 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Samsung Medical Center
06351 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Hospital Universitario 12 de Octubre
28041 Madrid
SpainRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

This study is open to adults with different types of advanced cancer (solid tumours). The

study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment

was not successful. In some countries, adolescents who are at least 15 years old and who are

diagnosed with NUT carcinoma can also participate. No standard treatment exists for this rare

and aggressive form of cancer.

The purpose of this study is to find out the highest dose of BI 894999 that people can

tolerate.

BI 894999 is tested for the first time in humans. Participants take tablets once daily. The

study also tests whether participants can tolerate BI 894999 better when taken continuously

or with breaks in between.

Participants can stay in the study as long as they benefit from the treatment and can

tolerate it.

The doctors also regularly check the general health of the participants.

Ein-/Ausschlusskriterien

Inclusion criteria:

For all patients

- Age 18 years or older at the time of signature of the informed consent.

- Life expectancy of at least 12 weeks after the start of the treatment according to the

investigator's judgement

- Male or female patients. Women of childbearing potential* must be ready and able to

use highly effective methods of birth control per ICH M3(R2) that result in a low

failure rate of less than 1% per year when used consistently and correctly. A list of

contraception methods meeting these criteria is provided in the patient information.

For women of childbearing potential using a contraceptive pill, an additional barrier

method is necessary due to the potential CYP3A4 inducing effect of BI894999. Male

patients having a partner of childbearing potential must use condoms and ensure their

partner is using a highly effective method of birth control as described above, during

the trial and for at least three months after the end of the trial * Any female who

has experienced menarche and does not meet the criteria for "women not of childbearing

potential" as described below.

Women not of childbearing potential are defined as: women who are postmenopausal (12 months

with no menses without an alternative medical cause) or who are permanently sterilized

(e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy).

- Written informed consent consistent with ICH-GCP and local legislation

For patients with solid tumours

- Patients with a histologically or cytologically confirmed diagnosis of an advanced

unresectable and/or metastatic, malignant solid tumour, who have failed conventional

treatment or for whom no therapy of proven efficacy exists, or who are not amenable to

standard therapies

- Age ≥ legal age to be adult for the given country at the time of signature of the

informed consent. For NC patients, age 15 years or older at the time of signature of

the informed consent ( in Germany and South Korea, only legally adult patients may be

included

- Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0 or 1 at the

time of screening. A score of 2 is allowed for NUT carcinoma patients

- Recovery of therapy-related toxicities from previous chemotherapy, tyrosine kinase

inhibitors, hormone therapy, immunotherapy, antibodies, vaccine therapy, or

radiotherapy to CTCAE ≤ grade 1 (with the exception of alopecia, peripheral sensory

neuropathy grade 2)

- Life expectancy of at least 12 weeks after the start of the treatment according to the

investigator's judgement

- Male or female patients. Women of childbearing potential* must be ready and able to

use highly effective methods of birth control per ICH M3(R2) that result in a low

failure rate of less than 1% per year when used consistently and correctly. A list of

contraception methods meeting these criteria is provided in the patient information.

For women of childbearing potential using a contraceptive pill, an additional barrier

method is necessary due to the potential CYP3A4 inducing effect of BI894999. Male

patients having a partner of childbearing potential must use condoms and ensure their

partner is using a highly effective method of birth control as described above, during

the trial and for at least three months after the end of the trial treatment

- Written informed consent consistent with ICH-GCP and local legislation. For adolescent

NC patients aged 15 years to < legal adult age, written assent of the patient and

written informed consent of the parents (both or one according to national regulation)

or legal guardian of the adolescent

- Written informed consent for tumour biopsies in the escalation phase Ia

- Optional for those patients until extension of the MTD cohort,

- Optional for the patients in the extension of MTD cohort at the same time points

as described below for the expansion phase. For these patients in the extension

of the MTD cohort, if they have an accessible lesion for biopsy, they will be

offered optional consent for tumour biopsies

- In addition, all patients included in the expansion Phase Ib must:

- Have been diagnosed with one of the four types of tumours selected:

- small cell lung cancer (SCLC)

- metastatic castrate resistant prostate cancer (mCRPC)

- colorectal cancer (CRC)

- NUT carcinoma (NC) (for which the "midline" origin is not a prerequisite)

- Have failed conventional treatments or who are not amenable to standard therapies (per

criterion 1) that specifically include for:

- SCLC: a platinum-based therapy (previous treatment with topotecan is not

mandatory)

- mCRPC: a hormonal agent (abiraterone, enzalutamide, or apalutamide) and a taxane

(docetaxel or cabazitaxel)

- CRC: fluoropyrimidine, oxaliplatin and irinotecan, bevacizumab for patients

eligible to this treatment and an anti-epidermal growth factor receptor (EGFR) in

RAS (Rat Sarcoma Virus) wild type metastatic CRC.

- Have measurable disease (radiated lesions and lesions used for biopsy do not qualify

as target lesions), according to RECIST 1.1 (R09-0262) (for NC patients only

nonmeasurable disease is acceptable); or according to PCWG3 (R17-3377) for the mCRPC

cohort (see point 5 of inclusion criteria below, specific to mCRPC patients)

- Have progressive disease within the last 6 months, according to RECIST 1.1 (R09-0262)

or according to PCWG3 (R17-3377) for the mCRPC cohort (see point 5 of inclusion

criteria below, specific to mCRPC patients). NC patients do not need to show

progression per RECIST 1.1 (for example, if newly diagnosed).

- Have a tumour lesion accessible for biopsies (pre- and at steady state under treatment

in Cycle 1, ideally from the same anatomic lesion) (except for mCRPC patients having

only bone metastases or for patients with therapeutic INR because of treatment with a

vitamin K antagonist or a novel oral anticoagulant. Biopsies are optional for NC

patients

- Give written informed consent for two tumour biopsies, one at screening and one after

start of treatment, between Day 8 and Day 11 of Cycle 1 (or between day 3 and day 8 if

the day of biopsy in Cycle 1 needs to be moved as explained in Section 3.1) (when

applicable)

- In addition, all patients in the mCRPC expansion cohort of Phase Ib must have:

- Histologically or cytologically confirmed adenocarcinoma of the prostate

- Radiographic evidence of metastatic prostate cancer (stage M1 or D2). Distant

metastases evaluable by bone scan, CT scan, or MRI within 28 days before the start of

study treatment.

- PSA ≥ 5 ng/mL (if no measurable disease by RECIST 1.1)

- Prior surgical or chemical castration with a serum testosterone of <50 ng/dL (< 1.7

nmol/L) by luteinizing hormone releasing level hormone (LHRH) agonist or antagonist,

or by abiraterone or by enzalutamide or apalutamide. If the actual method of

castration is LHRH agonist or antagonist, the patient must be willing to continue the

use of LHRH agonist or antagonist during protocol treatment.

- Progressive disease defined as at least one of the following:

- Progressive measurable disease: using conventional solid tumour criteria RECIST

1.1

- Bone scan progression: at least two new lesions on bone scan plus a rising PSA as

described in point c below

- Increasing PSA level: at least two consecutive rising PSA values over a reference

value (PSA no.1) taken at least 1 week apart. A third PSA (PSA no. 3) is required

to be > than PSA no. 2; if not, a fourth PSA (PSA no. 4) is required to be > to

PSA no. 2

In patients with DLBCL

- Patients with histologically confirmed DLBCL who have failed 2 or more lines of

systemic therapy including an anti-CD-20 therapy and an anthracycline or who are not

amenable to standard therapies but have an indication for therapy as per

investigator's judgement. Standard therapies may also include but are not limited to

CAR-T cells therapy, depending on approved therapies in the country where the patient

is treated

- ECOG Performance Status 0, 1 or 2 at the time of screening

- Measurable disease (radiated lesions do not qualify as target lesions) according to

according to RECIL 2017 on the CT scan part of the FDG/PET-CT scan

- Recovery of therapy-related toxicities from previous anti-lymphoma therapy to CTCAE <=

grade 1 (with the exception of alopecia, peripheral sensory neuropathy grade 2)

- written informed consent for tumour biopsies (optional)

- Further inclusion criteria apply

Exclusion criteria:

For all patients:

- Inability to swallow tablets

- Additional other serious illness, concomitant non-oncological disease (e.g. active

infectious disease including an active infection with SARS-CoV-2 confirmed by a PCR

test or had one in the prior 6 weeks or active hepatitis (Hep) B infection as defined

by positive Hep B DNA test, active Hep C infection as defined by positive Hep C RNA

test and human immunodeficiency virus (HIV) infection (positive result in established

HIV diagnostic assay), or ongoing toxicity from prior therapies considered by the

investigator to potentially compromise patient's safety in this trial

- Serum creatinine greater than 1.5 mg/dL (>132 µmol/L, SI unit equivalent)

- Women who are pregnant, nursing, or who plan to become pregnant while in the trial

- Treatment with other investigational drugs or participation in another clinical

interventional trial within the past four weeks or within five times the half-life of

the previous investigational drug, whichever is shorter, before start of therapy or

concomitant with this trial

- Patients unable to comply with the protocol

- Patients who are actively abusing alcohol or drugs. Since no alcohol or drug testing

is required per protocol, it is at the investigator's discretion to determine abuse.

For patients with solid tumours:

- Additional other serious illness , concomitant non-oncological disease (e.g. active

infectious disease or known chronic Hepatitis B/Hepatitis C infection and HIV), or

ongoing toxicity from prior therapies considered by the investigator to potentially

compromise patient's safety in this trial

- History or presence of cardiovascular abnormalities deemed clinically relevant by the

investigator such as uncontrolled hypertension, congestive heart failure NYHA

classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial

infarction within 6 months prior to study entry.Left Ventricular Ejection Fraction

(LVEF) less than 50% at baseline

- Clinical evidence of symptomatic progressive brain or leptomeningeal disease during

the last 28 days before the start of treatment with BI 894999

- Absolute neutrophil count less than 1500/mm^3

- Platelet count less than 100 000/mm^3

- Bilirubin greater than 1.5 mg/dL (>26 µmol/L, SI unit equivalent) (except known

Gilbert's syndrome, accepted up to 2 mg/dL or up to 34.2 µmol/L in this case)

- Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than

2.5 times the upper limit of normal (if related to liver metastases, greater than five

times the upper limit of normal)

- Treatment with other investigational drugs or participation in another clinical

interventional trial within the past four weeks (past two weeks for NC patients) or

within five times the half-life of the previous investigational drug, whichever is the

shorter, before start of therapy or concomitant with this trial

- Systemic anti-cancer therapy within four weeks (past two weeks for NC patients) or

five times the half-life of the drug, whichever is shorter. Radiotherapy given for

curative intent or other than palliative radiotherapy within the past four weeks

before start of therapy or concomitantly with this trial. This These restrictions does

not apply to LHRH agonists or antagonists, steroids (given at a stable dose in the

last four weeks) used for palliative intent, bisphosphonates, and denosumab and to

palliative radiotherapy (no wash out required)

For patients with DLBCL:

- Patient is eligible for curative salvage high dose therapy followed by stem cell

transplant.

- Primary central nervous system (CNS) lymphoma or known CNS involvement

- Prior allogeneic bone marrow or stem cell transplant

- High-dose therapy with stem cell support <3 months prior to visit 1

- AST or ALT >2.5 x upper limit of normal (CTCAE grade 2 or higher)

- Total bilirubin >1.5 x upper limit of normal (CTCAE grade 2 or higher)

- Absolute neutrophil count <1.0 x 10^9/L(without growth factor support)

- Platelets <100 x 10^9/L (without transfusions)

- Significant concurrent medical disease or condition which according to the

investigator's judgement would either compromise patient safety or interfere with the

evaluation of the safety of the test drug, e.g. symptomatic congestive heart failure,

unstable angina pectoris, myocardial infarction within 6 months prior to study entry,

cardiac arrhythmia requiring therapy with the exception of extra systoles or minor

conduction abnormalities

- Chronic or ongoing infection requiring treatment at the time of enrolment or within

the previous two weeks, e.g. active infectious disease or known Hepatitis B/Hepatitis

C infection, HIV

- Systemic anti-DLBCL therapy within the past two weeks or five times the half-life of

the drug, whichever is shorter (palliative radiotherapy and agents used for palliative

reasons for example steroids and bisphosphonates, are allowed)

- Further exclusion criteria apply

Studien-Rationale

Primary outcome:

1. In phase Ib: Number of patients experiencing DLTs from start of treatment until end of treatment (in all cycles) as assessed approximately every 3 weeks after Cycle 2 (at the end of each new cycle) in order to determine the recommended phase II dose (Time Frame - average of 12 months)

2. In phase Ia: Number of patients with DLT observed in the first cycle (first 21 days) for Schedules A and B, first 28 days for Schedule C), to meet objective of assessing MTD for each schedule in solid tumour patients & in schedule B in the DLBCL cohort (Time Frame - Up to 4 weeks)

Secondary outcome:

1. efficacy endpoint in phases Ia and Ib: Objective response (OR), defined as CR or PR with tumour assessment during treatment period for each schedule (Time Frame - every 6 weeks, average of 4 months)

2. efficacy endpoint in phase Ib: Progression-free Survival (PFS) or radiological PFS (Time Frame - average of 5 months)

3. efficacy endpoint in phase Ib: Best overall response with an evaluation of approximately every 2 cycles (6 weeks if no delays) during the entire treatment period (Time Frame - every 6 weeks, average of 4 months)

4. In both phases: Cmax,ss after single dose and at steady state, as measured during the first cycle (3 weeks) for Schedules A and B, the first 4 weeks for Schedule C) (Time Frame - up to 4 weeks)

5. In both phases: AUC0-24 after single dose and at steady state, as measured during the first cycle (3 weeks) for Schedules A and B, the first 4 weeks for Schedule C) (Time Frame - up to 4 weeks)

6. In both phases: AUC tau, ss after single dose and at steady state, as measured during the first cycle (3 weeks) for Schedules A and B, the first 4 weeks for Schedule C) (Time Frame - up to 4 weeks)

7. Phase Ia: Number of patients experiencing DLTs from start of treatment until end of treatment (in all cycles) for each of the schedules (A, B and C) in patients with solid tumours and in schedule B in the DLBCL cohort (Time Frame - average of 12 months)

8. In both phases: Cmax after single dose and at steady state, as measured during the first cycle (3 weeks) for Schedules A and B, the first 4 weeks for Schedule C) (Time Frame - up to 4 weeks)

9. efficacy endpoint in phase Ib: Prostate Specific Antigen (PSA) response (decline in PSA value ≥50% from baseline) in patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (Time Frame - average of 12 months)

10. Overall survival in patients with NUT Carcinoma (NC) (Time Frame - Up to 29 months)

Studien-Arme

  • Experimental: arm A
    once daily continuous oral intake in 3-week cycles
  • Experimental: arm B
    once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles
  • Experimental: arm C
    one week on followed by one week off treatment, repeated every two weeks in 4-week cycles

Geprüfte Regime

  • BI 894999:
    day 1 to day 21 in 3-week cycles
  • BI 894999:
    day 1 to day 14 followed by a week off in 3-week cycles in schedule B
  • BI 894999:
    one week on followed by one week off treatment, repeated every two weeks in 4-week cycles

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Männer sind Vorsorgemuffel bei Krebsfrüherkennung
M%C3%A4nner+sind+Vorsorgemuffel+bei+Krebsfr%C3%BCherkennung
© deagreez / Fotolia.com

In Deutschland geht nur gut jeder neunte Mann zur Prostatakrebsvorsorge. 4,65 Millionen und zwar 11,7 Prozent aller anspruchsberechtigten Bürger nahmen im Jahr 2014 die kostenlose Früherkennungsuntersuchung wahr, wie die BARMER GEK zum Weltmännertag am 3. November mitteilt. Damit bleiben Männer Präventionsmuffel. Denn im Jahr 2010 absolvierten 11,41 Prozent den Check. „Eine Krebsvorsorgeuntersuchung kann Leben...